AstraZeneca Pays Dynavax $3M to Speed Up Start of Asthma Drug Trials – Genetic Engineering News


Proactive Investors USA & Canada

AstraZeneca Pays Dynavax $3M to Speed Up Start of Asthma Drug Trials
Genetic Engineering News
Dynavax Technologies will receive a $3 million payment from AstraZeneca to fund the initiation of clinical trials with their partnered asthma drug AZD 1419. The payment comes as part of the firms' amended collaboration to accelerate the start of
AstraZeneca, Dynavax amend agreement to accelerate development of asthma drugProactive Investors USA & Canada
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for AsthmaMarketWatch (press release)
Dynavax Technologies Corporation partners with AstraZeneca to advance AZD 1419 Middle East North Africa Financial Network
Bizjournals.com (blog)
all 15 news articles »

View full post on asthma – Google News

Common Asthma Drug Could Speed MS Treatment – BusinessWeek

Common Asthma Drug Could Speed MS Treatment
BusinessWeek
13 (HealthDay News) — A common asthma drug might accelerate the benefits of treatment for multiple sclerosis when combined with standard medicine,
Asthma drug albuterol improves multiple sclerosis when added to conventional Los Angeles Times
Asthma drug may help multiple sclerosis: studyReuters
Asthma Drug May Help MS PatientsMedPage Today
EurekAlert (press release)
all 16 news articles »

View full post on asthma – Google News

NIH teams with Pay.gov to speed tech-transfer payments

A new payment site within Pay.gov will make it easier for companies that license
inventions owned by the National Institutes of Health and the Food and Drug
Administration to make their royalty payments. Royalties are typically paid
upfront for biological materials and over the term of a commercial patent
license. The project is led by the Office of Technology Transfer and the
Office of Financial Management at NIH.

View full post on National Institutes of Health (NIH) News Releases